Otros idiomas HUTCHMED (China) Limited

Acciones

HCM

KYG4672N1198

Mercado cerrado - London S.E. Otros sitios de cotización 17:35:09 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
290 ^GBX	-4,61 %		+7,41 %	+2,47 %

26/04	Hutchmed toma nota de la opinión positiva del CHMP para la aprobación del fruiquintinib	AN
26/04	El Comité de la Agencia Europea del Medicamento respalda la aprobación de fruquintinib de Takeda para tratar el cáncer colorrectal	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26/04
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26/04
Hutchmed to Present New Data at US Cancer Research Conference	05/04
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	05/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Hutchmed lung cancer treatment accepted for review in China	28/03
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	28/03
JD Sports backs outlook; Spirent accepts new offer	28/03
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	28/03
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	28/03
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	22/03
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	22/03
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	22/03
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	22/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas HUTCHMED (China) Limited

Acciones

HCM

KYG4672N1198

Otros idiomas

Filtros